TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A New School-based Drug Prevention Programme for Teenagers: Interventions That Target Personality Risk for Substance Abuse and Mental Illness
Brief Summary: Personality targeted cognitive behavioural interventions have been shown to be effective in reducing alcohol and drug misuse in adult substance abusers (Conrod et al., 2000) and adolescent drinkers (Conrod et al, in press). As these interventions target personality traits linked to risk for addictive and non-addictive mental disorders, the aim of this study is to examine the extent to which this approach can prevent and/or reduce alcohol and drug misuse as well as have an impact on the onset or severity of emotional and behavioural problems in young people.


Options:
A: Arm Label: Fruit and Vegetable Intake Behavioral Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Fruit and vegetable intake in rural youth | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Fruit and vegetable intake in rural youth; Assigned to Arm(s): Fruit and Vegetable Intake Behavioral Intervention
B: Arm Label: COPE/Healthy Lifestyles TEEN Program; Type: EXPERIMENTAL; Interventions: Behavioral: COPE/Healthy Lifestyles TEEN Program. | Arm Label: Healthy Teens Attention Control Program; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Healthy Teens Attention Control Program | Intervention Type: BEHAVIORAL; Name: COPE/Healthy Lifestyles TEEN Program.; Assigned to Arm(s): COPE/Healthy Lifestyles TEEN Program | Intervention Type: BEHAVIORAL; Name: Healthy Teens Attention Control Program; Assigned to Arm(s): Healthy Teens Attention Control Program
C: Arm Label: learning to cope with your impulsivity; Type: EXPERIMENTAL; Interventions: Behavioral: PRE-Venture: Personality Risk Education | Arm Label: learning to cope with your sensation seeking; Type: EXPERIMENTAL; Interventions: Behavioral: PRE-Venture: Personality Risk Education | Arm Label: learning to cope with your anxiety sensitivity; Type: EXPERIMENTAL; Interventions: Behavioral: PRE-Venture: Personality Risk Education | Arm Label: learning to manage your negative thinking; Type: EXPERIMENTAL; Interventions: Behavioral: PRE-Venture: Personality Risk Education | Intervention Type: BEHAVIORAL; Name: PRE-Venture: Personality Risk Education; Assigned to Arm(s): learning to cope with your anxiety sensitivity, learning to cope with your impulsivity, learning to cope with your sensation seeking, learning to manage your negative thinking
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Adapted Motivational Interviewing & Skills Training | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Adapted Motivational Interviewing & Skills Training | Arm Label: 3; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Adapted Motivational Interviewing & Skills Training; Assigned to Arm(s): 1, 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Management of Antipsychotic Medication Associated Obesity
Brief Summary: This program aims to help Veterans who take antipsychotic medications lose weight. The investigators use a program based on the American Diabetes Association's "Diabetes Prevention Program," and the investigators have modified it to fit the lifestyles of people with mental illness. All participants are educated about nutrition and cutting down fat intake, how and when to exercise, and the causes of diabetes and how to prevent it. Participants must be Veterans who live within one hour of the West Los Angeles VA hospital.


Options:
A: Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Lifestyle Balance; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Behavioral Weight Loss Program | Intervention Type: BEHAVIORAL; Name: Behavioral Weight Loss Program; Assigned to Arm(s): Lifestyle Balance
B: Arm Label: Lifestyle intervention to increase physical activity; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: lifestyle intervention to increase physical activity | Arm Label: waiting control group; Type: NO_INTERVENTION; Interventions: Behavioral: lifestyle intervention to increase physical activity | Intervention Type: BEHAVIORAL; Name: lifestyle intervention to increase physical activity; Assigned to Arm(s): Lifestyle intervention to increase physical activity, waiting control group
C: Arm Label: In SHAPE; Type: EXPERIMENTAL; Interventions: Behavioral: In SHAPE, Behavioral: Fitness Club Membership | Arm Label: Fitness Club Membership; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Fitness Club Membership | Intervention Type: BEHAVIORAL; Name: In SHAPE; Assigned to Arm(s): In SHAPE | Intervention Type: BEHAVIORAL; Name: Fitness Club Membership; Assigned to Arm(s): Fitness Club Membership, In SHAPE
D: Arm Label: Lifestyle Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle Intervention | Arm Label: Diabetes Support and Education; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Diabetes Support and Education | Intervention Type: BEHAVIORAL; Name: Lifestyle Intervention; Assigned to Arm(s): Lifestyle Intervention | Intervention Type: BEHAVIORAL; Name: Diabetes Support and Education; Assigned to Arm(s): Diabetes Support and Education

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure (OPTIMIZE-HF): An Internet-based Registry and Process of Care Improvement Program for Heart Failure Patients
Brief Summary: This program is designed to improve medical care and education of hospitalized patients with heart failure and accelerate the initiation of evidence-based heart failure guideline recommended therapies by administering them before hospital discharge. A registry component focusing on admission to discharge and 60- to 90-day follow-up is designed to evaluate the demographic, pathophysiologic, clinical, treatment, and outcome characteristics of patients hospitalized with heart failure.


Options:
A: Intervention Type: DRUG; Name: Beta-blockers including Carvedilol; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: ACE inhibitors; Assigned to Arm(s): N/A
B: Intervention Type: PROCEDURE; Name: Percutaneous coronary angioplasty/intervention (PCI); Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Anti-ischemic drug therapy; Assigned to Arm(s): N/A
C: Arm Label: Enoxaparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: enoxaparin | Arm Label: Fondaparinux; Type: EXPERIMENTAL; Interventions: Drug: Fondaparinux | Intervention Type: DRUG; Name: Fondaparinux; Assigned to Arm(s): Fondaparinux | Intervention Type: DRUG; Name: enoxaparin; Assigned to Arm(s): Enoxaparin
D: Intervention Type: BEHAVIORAL; Name: Pharmacist intervention; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure (OPTIMIZE-HF): An Internet-based Registry and Process of Care Improvement Program for Heart Failure Patients
Brief Summary: This program is designed to improve medical care and education of hospitalized patients with heart failure and accelerate the initiation of evidence-based heart failure guideline recommended therapies by administering them before hospital discharge. A registry component focusing on admission to discharge and 60- to 90-day follow-up is designed to evaluate the demographic, pathophysiologic, clinical, treatment, and outcome characteristics of patients hospitalized with heart failure.


Options:
A: Arm Label: Ultrafiltration Group; Type: ACTIVE_COMPARATOR; Interventions: Device: CHIARA-System | Arm Label: Control group (Usual care IV diuretics); Type: OTHER; Interventions: Other: Usual care IV diuretics | Intervention Type: DEVICE; Name: CHIARA-System; Assigned to Arm(s): Ultrafiltration Group | Intervention Type: OTHER; Name: Usual care IV diuretics; Assigned to Arm(s): Control group (Usual care IV diuretics)
B: Intervention Type: DEVICE; Name: Aquadex system; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: IV diuretic; Assigned to Arm(s): N/A
C: Arm Label: Serelaxin (RLX030); Type: EXPERIMENTAL; Interventions: Drug: RLX030 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: RLX030; Assigned to Arm(s): Serelaxin (RLX030) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Intervention Type: DRUG; Name: Beta-blockers including Carvedilol; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: ACE inhibitors; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Double-Blind Pilot Study of Memantine Augmentation in Antidepressant Nonresponders or Incomplete Responders
Brief Summary: This study is evaluating the efficacy and safety of the drug memantine (trade name NAMENDA) as an augmentation agent for the treatment of depression in people who are not fully responding to antidepressant medications.


Options:
A: Arm Label: Ketamine; Type: EXPERIMENTAL; Interventions: Drug: Ketamine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Ketamine; Assigned to Arm(s): Ketamine | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
B: Arm Label: AZD6765 (150 mg) / Placebo; Type: EXPERIMENTAL; Interventions: Drug: AZD6765 | Arm Label: Placebo / AZD6765 (150 mg); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo to AZD6765 | Intervention Type: DRUG; Name: AZD6765; Assigned to Arm(s): AZD6765 (150 mg) / Placebo | Intervention Type: DRUG; Name: Placebo to AZD6765; Assigned to Arm(s): Placebo / AZD6765 (150 mg)
C: Arm Label: memantine; Type: EXPERIMENTAL; Interventions: Drug: memantine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: memantine; Assigned to Arm(s): memantine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Esketamine + Standard of care; Type: EXPERIMENTAL; Interventions: Drug: Esketamine, Other: Standard of Care | Arm Label: Placebo + Standard of care; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo, Other: Standard of Care | Intervention Type: DRUG; Name: Esketamine; Assigned to Arm(s): Esketamine + Standard of care | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo + Standard of care | Intervention Type: OTHER; Name: Standard of Care; Assigned to Arm(s): Esketamine + Standard of care, Placebo + Standard of care

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Double-Blind Pilot Study of Memantine Augmentation in Antidepressant Nonresponders or Incomplete Responders
Brief Summary: This study is evaluating the efficacy and safety of the drug memantine (trade name NAMENDA) as an augmentation agent for the treatment of depression in people who are not fully responding to antidepressant medications.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: AZD6765 | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ketamine | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: AZD6765; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Ketamine; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3
B: Arm Label: Esketamine 14 mg; Type: EXPERIMENTAL; Interventions: Drug: Esketamine 14 mg, Drug: Esketamine 56 mg, Drug: Placebo | Arm Label: Esketamine 28 mg; Type: EXPERIMENTAL; Interventions: Drug: Esketamine 28 mg, Drug: Esketamine 56 mg, Drug: Placebo | Arm Label: Esketamine 56 mg; Type: EXPERIMENTAL; Interventions: Drug: Esketamine 56 mg, Drug: Placebo | Arm Label: Esketamine 84 mg; Type: EXPERIMENTAL; Interventions: Drug: Esketamine 56 mg, Drug: Esketamine 84 mg, Drug: Placebo | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Esketamine 14 mg, Drug: Esketamine 28 mg, Drug: Esketamine 56 mg, Drug: Esketamine 84 mg, Drug: Placebo | Intervention Type: DRUG; Name: Esketamine 14 mg; Assigned to Arm(s): Esketamine 14 mg, Placebo | Intervention Type: DRUG; Name: Esketamine 28 mg; Assigned to Arm(s): Esketamine 28 mg, Placebo | Intervention Type: DRUG; Name: Esketamine 56 mg; Assigned to Arm(s): Esketamine 14 mg, Esketamine 28 mg, Esketamine 56 mg, Esketamine 84 mg, Placebo | Intervention Type: DRUG; Name: Esketamine 84 mg; Assigned to Arm(s): Esketamine 84 mg, Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Esketamine 14 mg, Esketamine 28 mg, Esketamine 56 mg, Esketamine 84 mg, Placebo
C: Arm Label: memantine; Type: EXPERIMENTAL; Interventions: Drug: memantine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: memantine; Assigned to Arm(s): memantine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Omega-3; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Smoothie 1g Eicosapentaneoic Acid (EPA) and 1g Docoshaexanoic Acid (DHA) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Smoothie 1g Eicosapentaneoic Acid (EPA) and 1g Docoshaexanoic Acid (DHA) | Intervention Type: DIETARY_SUPPLEMENT; Name: Smoothie 1g Eicosapentaneoic Acid (EPA) and 1g Docoshaexanoic Acid (DHA); Assigned to Arm(s): Omega-3, Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Double-Blind Pilot Study of Memantine Augmentation in Antidepressant Nonresponders or Incomplete Responders
Brief Summary: This study is evaluating the efficacy and safety of the drug memantine (trade name NAMENDA) as an augmentation agent for the treatment of depression in people who are not fully responding to antidepressant medications.


Options:
A: Arm Label: memantine; Type: EXPERIMENTAL; Interventions: Drug: memantine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: memantine; Assigned to Arm(s): memantine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Memantine 1; Type: EXPERIMENTAL; Interventions: Drug: Memantine Hydrochloride (HCl) | Arm Label: Memantine 2; Type: EXPERIMENTAL; Interventions: Drug: Memantine Hydrochloride (HCl) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo capsules | Intervention Type: DRUG; Name: Memantine Hydrochloride (HCl); Assigned to Arm(s): Memantine 1 | Intervention Type: DRUG; Name: Memantine Hydrochloride (HCl); Assigned to Arm(s): Memantine 2 | Intervention Type: DRUG; Name: Placebo capsules; Assigned to Arm(s): Placebo
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: memantine; Type: ACTIVE_COMPARATOR; Interventions: Drug: memantine | Intervention Type: DRUG; Name: memantine; Assigned to Arm(s): memantine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Memantine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Memantine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Memantine; Assigned to Arm(s): Memantine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: The purpose of this study is to 1) evaluate the safety and efficacy of two doses of bupropion SR (150mg/day and 300mg/day) when compared to placebo, as an aid to smoking cessation in adolescents and 2) to examine which factors, such as medication adherence, nicotine dependence, and motivation to quit, affect treatment outcome.


Options:
A: Arm Label: Bupropion SR; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion SR | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Oral Tablet | Intervention Type: DRUG; Name: Bupropion SR; Assigned to Arm(s): Bupropion SR | Intervention Type: DRUG; Name: Placebo Oral Tablet; Assigned to Arm(s): Placebo
B: Arm Label: Bupropion and Weight Concerns intervention; Type: EXPERIMENTAL; Interventions: Drug: Bupropion, Behavioral: weight concerns intervention | Arm Label: Placebo and Weight Concerns; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo, Behavioral: weight concerns intervention | Arm Label: Bupropion and standard smoking cessation; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion, Behavioral: smoking cessation intervention | Arm Label: Placebo and standard smoking cessation; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Behavioral: smoking cessation intervention | Intervention Type: DRUG; Name: Bupropion; Assigned to Arm(s): Bupropion and Weight Concerns intervention, Bupropion and standard smoking cessation | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo and Weight Concerns, Placebo and standard smoking cessation | Intervention Type: BEHAVIORAL; Name: weight concerns intervention; Assigned to Arm(s): Bupropion and Weight Concerns intervention, Placebo and Weight Concerns | Intervention Type: BEHAVIORAL; Name: smoking cessation intervention; Assigned to Arm(s): Bupropion and standard smoking cessation, Placebo and standard smoking cessation
C: Arm Label: varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: varenicline tartrate (CP-526, 555-18) | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: varenicline tartrate (CP-526, 555-18); Assigned to Arm(s): varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo
D: Intervention Type: DRUG; Name: bupropion SR; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: The purpose of this study is to 1) evaluate the safety and efficacy of two doses of bupropion SR (150mg/day and 300mg/day) when compared to placebo, as an aid to smoking cessation in adolescents and 2) to examine which factors, such as medication adherence, nicotine dependence, and motivation to quit, affect treatment outcome.


Options:
A: Arm Label: varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: Nicotine Patches only; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine patches | Arm Label: Nicotine Patches with Nicotine Inhaler; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine patches, Drug: Nicotine Inhaler | Arm Label: varenicline with bupropion; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline, Drug: Bupropion | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): varenicline, varenicline with bupropion | Intervention Type: DRUG; Name: Bupropion; Assigned to Arm(s): varenicline with bupropion | Intervention Type: DRUG; Name: Nicotine patches; Assigned to Arm(s): Nicotine Patches only, Nicotine Patches with Nicotine Inhaler | Intervention Type: DRUG; Name: Nicotine Inhaler; Assigned to Arm(s): Nicotine Patches with Nicotine Inhaler
B: Intervention Type: DRUG; Name: bupropion SR (sustained-release); Assigned to Arm(s): N/A
C: Arm Label: patch; Type: ACTIVE_COMPARATOR; Interventions: Drug: nicotine patch | Arm Label: nicotine lozenge; Type: ACTIVE_COMPARATOR; Interventions: Drug: nicotine lozenge | Arm Label: bupropion; Type: ACTIVE_COMPARATOR; Interventions: Drug: bupropion | Arm Label: patch + lozenge; Type: ACTIVE_COMPARATOR; Interventions: Drug: patch + lozenge | Arm Label: buproion + lozenge; Type: ACTIVE_COMPARATOR; Interventions: Drug: bupropion + lozenge | Intervention Type: DRUG; Name: nicotine patch; Assigned to Arm(s): patch | Intervention Type: DRUG; Name: nicotine patch; Assigned to Arm(s): patch | Intervention Type: DRUG; Name: nicotine lozenge; Assigned to Arm(s): nicotine lozenge | Intervention Type: DRUG; Name: bupropion; Assigned to Arm(s): bupropion | Intervention Type: DRUG; Name: patch + lozenge; Assigned to Arm(s): patch + lozenge | Intervention Type: DRUG; Name: bupropion + lozenge; Assigned to Arm(s): buproion + lozenge
D: Intervention Type: DRUG; Name: bupropion SR; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: The purpose of this study is to 1) evaluate the safety and efficacy of two doses of bupropion SR (150mg/day and 300mg/day) when compared to placebo, as an aid to smoking cessation in adolescents and 2) to examine which factors, such as medication adherence, nicotine dependence, and motivation to quit, affect treatment outcome.


Options:
A: Arm Label: Bupropion SR; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion SR | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Oral Tablet | Intervention Type: DRUG; Name: Bupropion SR; Assigned to Arm(s): Bupropion SR | Intervention Type: DRUG; Name: Placebo Oral Tablet; Assigned to Arm(s): Placebo
B: Intervention Type: DRUG; Name: bupropion SR; Assigned to Arm(s): N/A
C: Arm Label: NRT arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine Replacement Therapy (NRT) | Arm Label: NRT and HIV Tailored Quit Smoking Counseling; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine Replacement Therapy (NRT), Behavioral: HIV Tailored Quit Smoking Counseling | Arm Label: Varenicline (VR) Arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: Varenicline (VR) and HIV Tailored Quit Smoking Counseling; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline, Behavioral: HIV Tailored Quit Smoking Counseling | Intervention Type: DRUG; Name: Nicotine Replacement Therapy (NRT); Assigned to Arm(s): NRT and HIV Tailored Quit Smoking Counseling, NRT arm | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline (VR) Arm, Varenicline (VR) and HIV Tailored Quit Smoking Counseling | Intervention Type: BEHAVIORAL; Name: HIV Tailored Quit Smoking Counseling; Assigned to Arm(s): NRT and HIV Tailored Quit Smoking Counseling, Varenicline (VR) and HIV Tailored Quit Smoking Counseling
D: Arm Label: Sugar Pill; Type: PLACEBO_COMPARATOR; Interventions: Other: Sugar Pill | Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Bupropion HCl; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion HCl | Intervention Type: OTHER; Name: Sugar Pill; Assigned to Arm(s): Sugar Pill | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Bupropion HCl; Assigned to Arm(s): Bupropion HCl

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: The purpose of this study is to 1) evaluate the safety and efficacy of two doses of bupropion SR (150mg/day and 300mg/day) when compared to placebo, as an aid to smoking cessation in adolescents and 2) to examine which factors, such as medication adherence, nicotine dependence, and motivation to quit, affect treatment outcome.


Options:
A: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Photoaging mobile app promoting poster campaign. | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Photoaging mobile app promoting poster campaign.; Assigned to Arm(s): Intervention
B: Arm Label: SMS USA; Type: EXPERIMENTAL; Interventions: Behavioral: SMS USA | Arm Label: Attention matched control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: SMS USA; Assigned to Arm(s): SMS USA
C: Arm Label: "Intervention" group; Type: EXPERIMENTAL; Interventions: Behavioral: TABADO program | Arm Label: "Control" group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: TABADO program; Assigned to Arm(s): "Intervention" group
D: Intervention Type: DRUG; Name: bupropion SR; Assigned to Arm(s): N/A

Answer: D